CA2996542C - 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases - Google Patents

5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases Download PDF

Info

Publication number
CA2996542C
CA2996542C CA2996542A CA2996542A CA2996542C CA 2996542 C CA2996542 C CA 2996542C CA 2996542 A CA2996542 A CA 2996542A CA 2996542 A CA2996542 A CA 2996542A CA 2996542 C CA2996542 C CA 2996542C
Authority
CA
Canada
Prior art keywords
app
compounds
secretase
compound
bace
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2996542A
Other languages
English (en)
French (fr)
Other versions
CA2996542A1 (en
Inventor
Varghese John
Oleksandr Buzko
Dale Bredesen
Patricia SPILMAN
Barbara Jagodzinska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantneuro LLC
Original Assignee
Nantneuro LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantneuro LLC filed Critical Nantneuro LLC
Priority to CA3096896A priority Critical patent/CA3096896A1/en
Publication of CA2996542A1 publication Critical patent/CA2996542A1/en
Application granted granted Critical
Publication of CA2996542C publication Critical patent/CA2996542C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2996542A 2015-08-27 2016-08-29 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases Active CA2996542C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3096896A CA3096896A1 (en) 2015-08-27 2016-08-29 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210945P 2015-08-27 2015-08-27
US62/210,945 2015-08-27
PCT/US2016/049271 WO2017035529A1 (en) 2015-08-27 2016-08-29 Compositions for app-selective bace inhibition and uses therfor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3096896A Division CA3096896A1 (en) 2015-08-27 2016-08-29 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases

Publications (2)

Publication Number Publication Date
CA2996542A1 CA2996542A1 (en) 2017-03-02
CA2996542C true CA2996542C (en) 2020-12-29

Family

ID=58101012

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2996542A Active CA2996542C (en) 2015-08-27 2016-08-29 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases
CA3096896A Abandoned CA3096896A1 (en) 2015-08-27 2016-08-29 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3096896A Abandoned CA3096896A1 (en) 2015-08-27 2016-08-29 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases

Country Status (8)

Country Link
US (1) US11142505B2 (cg-RX-API-DMAC7.html)
EP (1) EP3341362B1 (cg-RX-API-DMAC7.html)
JP (2) JP2018525447A (cg-RX-API-DMAC7.html)
KR (1) KR20180090778A (cg-RX-API-DMAC7.html)
CN (1) CN108349905A (cg-RX-API-DMAC7.html)
AU (1) AU2016311502B2 (cg-RX-API-DMAC7.html)
CA (2) CA2996542C (cg-RX-API-DMAC7.html)
WO (1) WO2017035529A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2956443B1 (en) 2013-02-12 2019-09-25 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
CA2996542C (en) * 2015-08-27 2020-12-29 Nantneuro, Llc 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases
EP3759079A4 (en) * 2018-03-01 2021-11-17 The Regents Of The University Of California AMYLOID PROTEIN SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE
US11926599B1 (en) 2023-10-23 2024-03-12 King Faisal University 1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione as an antimicrobial compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU646877B2 (en) 1990-06-15 1994-03-10 Scios Nova Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
CA2101774C (en) 1991-01-21 2011-01-04 John A. Hardy Test and model for alzheimer's disease
PT620849E (pt) 1992-01-07 2003-11-28 Elan Pharm Inc Modelos animais transgenicos para a doenca de alzheimer
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
EP0871720A2 (en) 1995-06-07 1998-10-21 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
EP1115874B1 (en) 1998-09-24 2009-01-07 Pharmacia & Upjohn Company LLC Alzheimer's disease secretase
AU2005264915A1 (en) * 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
EP1896448A1 (en) * 2005-06-30 2008-03-12 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
JP2009509957A (ja) * 2005-09-26 2009-03-12 ワイス β−セクレターゼ阻害剤としてのアミノ−５−［４−（ジフルオロメトキシ）フェニル］−５−フェニルイミダゾロン化合物
WO2007078813A2 (en) 2005-12-19 2007-07-12 Wyeth 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION
AR065814A1 (es) * 2007-03-23 2009-07-01 Wyeth Corp Derivados de 5-fenilimidazolona,inhibidores de beta-secretasa,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos asociados a niveles beta-amiloides elevados.
EP2956443B1 (en) * 2013-02-12 2019-09-25 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
US9980769B2 (en) 2014-04-08 2018-05-29 Ethicon Llc Methods and devices for controlling motorized surgical devices
CA2996542C (en) 2015-08-27 2020-12-29 Nantneuro, Llc 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases
WO2019005297A1 (en) 2017-06-28 2019-01-03 Nantbio, Inc. BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP3759079A4 (en) * 2018-03-01 2021-11-17 The Regents Of The University Of California AMYLOID PROTEIN SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE

Also Published As

Publication number Publication date
CA3096896A1 (en) 2017-03-02
CA2996542A1 (en) 2017-03-02
WO2017035529A1 (en) 2017-03-02
US20190077766A1 (en) 2019-03-14
US11142505B2 (en) 2021-10-12
KR20180090778A (ko) 2018-08-13
WO2017035529A9 (en) 2017-08-24
EP3341362B1 (en) 2023-07-05
JP2018525447A (ja) 2018-09-06
AU2016311502B2 (en) 2019-07-18
EP3341362A4 (en) 2019-06-12
JP2021001188A (ja) 2021-01-07
EP3341362A1 (en) 2018-07-04
CN108349905A (zh) 2018-07-31
AU2016311502A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
US20250092361A1 (en) Method of inhibiting tau phosphorylation
US9572820B2 (en) Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
Burgess et al. Synthesis, structure− activity relationship, and mode-of-action studies of antimalarial reversed chloroquine compounds
JP6482458B2 (ja) Ａｐｐ特異性のｂａｃｅ（ａｓｂｉ）およびその使用
CA2996542C (en) 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases
CA2899938C (en) Hydantoins that modulate bace-mediated app processing
US20200115320A1 (en) Therapeutic compounds and methods of use
Li et al. Discovery of the polyamine conjugate with benzo [cd] indol-2 (1 H)-one as a lysosome-targeted antimetastatic agent
Cao et al. Benzodiazepine derivatives as potent vasopressin V2 receptor antagonists for the treatment of autosomal dominant kidney disease
AU2008229483A1 (en) Kinase protein binding inhibitors
CA3010883A1 (en) Methods for the treatment of myeloid derived suppressor cells related disorders
CN110049976A (zh) 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物
US20050256181A1 (en) Treating a viral disorder
US20140094482A1 (en) Benzazocine-ring compound inhibition of tau hyperphosphorylation
Cannazza et al. A novel class of allosteric modulators of AMPA/Kainate receptors
JP2008530999A (ja) ミクログリア促進アミロイド形成のアッセイ
Onwuha-Ekpete A Study on the Clinical Relevance of Metalloproteinase Inhibition
Kubo et al. Yoshiyuki Hirata1, 2, Tsutomu Sasaki3, Hideaki Kanki3, Chi-Jing Choong3, Kumiko Nishiyama3

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180725